Drugs & Targets Xtandi Receives FDA Approval for Supplemental New Drug Application October 28, 2016Vol.42 No.40
Drugs & Targets Keytruda Is First Checkpoint Inhibitor To Get Approval for Front Line NSCLC October 28, 2016Vol.42 No.40
Drugs & Targets Lartruvo Gets Accelerated Approval for Sarcoma; Tecentriq Approved for a Type of NSCLC October 21, 2016Vol.42 No.39
Drugs & Targets IBM Watson Health and Quest Diagnostics launched IBM Watson Genomics from Quest Diagnostics October 21, 2016Vol.42 No.39
Drugs & Targets CDC recommended 11-to-12-year-olds receive two doses of HPV vaccine October 21, 2016Vol.42 No.39
Drugs & Targets Onivyde in combination with 5-fluorouracil and leucovorin received marketing authorization from The European Commission October 21, 2016Vol.42 No.39
Drugs & Targets Venclyxto granted a positive opinion from the European Committee for Medicinal Products for Human Use October 21, 2016Vol.42 No.39
Drugs & Targets Genentech receives second Breakthrough Therapy Designation from FDA for Alecensa October 20, 2016Vol.39 No.09
